linjc16/ctgov huggingface dataset:
Desmopressin for Bleeding Related to Low Body Temperature

Study Overview
=================
Brief Summary
-----------------
To study, with a prospective randomised controlled design, whether the subcutaneous administration of the haemostatic drug desmopressin, may improve the impairment of primary haemostasis due to mildly decreased temperature.

Official Title
-----------------
Effect of Desmopressin on Platelet Dysfunction Associated With Mild Hypothermia in Healthy Volunteers

Conditions
-----------------
Hypothermia Induced Impairment of Primary Haemostasis

Intervention / Treatment
-----------------
* Drug: desmopressin
* Drug: desmopressin
* Drug: desmopressin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Healthy volunteers Exclusion Criteria: Any known platelet or coagulation disorder. Pregnant or lactating women. Known chronic liver or renal disease. Coronary artery, carotid artery or peripheral artery disease Recent history of taking antiplatelet drugs, anticoagulants or herbal preparations. Smoker or alcohol user Mentally incapable of providing informed consent Students or junior staff members who had direct working relationship with the PI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: desmopressin 1.5<br> | Drug: desmopressin<br>* single desmopressin subcutaneous injection, 1.5mcg<br>|
| Active Comparator: desmopressin 3<br> | Drug: desmopressin<br>* single desmopressin subcutaneous injection, 3mcg<br>|
| Active Comparator: desmopressin 15<br> | Drug: desmopressin<br>* single desmopressin subcutaneous injection, 15mcg<br>|
| Placebo Comparator: placebo<br> | Drug: placebo<br>* saline subcutaneous<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| closure time on PFA-100 |  | 3 hours |
Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions

Study Overview
=================
Brief Summary
-----------------
The use of Bone Marrow Autologous Collection (BMAC) in musculoskeletal conditions including osteoarthritis and tendon injuries has been growing. Outcome evidence continues to be sparse. The purpose of this study is collect a longitudinal case series of patient reported outcomes following BMAC injections for musculoskeletal conditions including osteoarthritis, tendinopathy and injuries to ligaments, tendons and muscles.

Official Title
-----------------
Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions

Conditions
-----------------
Musculoskeletal Pain, Osteoarthritis, Tendinopathy, Sprains Strain

Intervention / Treatment
-----------------
* Procedure: Bone Marrow Aspirate Concentrate Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Musculoskeletal Condition that is able to undergo an injection Patient requests the procedure and enrolls with agreement to pay for the procedure Exclusion Criteria: Active Cancer Allergies to local anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BMAC Group<br>Intervention Group | Procedure: Bone Marrow Aspirate Concentrate Injection<br>* BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC Score | Pain and Function Score | 5 years |
The Role of Antibiotics After Surgical Treatment of Simple Hand Infections: A Prospective Study

Study Overview
=================
Brief Summary
-----------------
Three patient groups with simple hand infections are tested regarding the necessity of antibiotics after surgical treatment.

Conditions
-----------------
Hand Infections

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with simple hand infections Exclusion Criteria: Infection of the bone, tendon or joint Major diseases like diabetes or immunodeficiency Systemic manifestations like fever or lymphangitis Bite infections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Systemic and local antibiotics<br> | Other: No intervention<br>* No intervention<br>* Other names: Since our study was observational after the beginning of treatment with or without antibiotics no intervention was influenced by the study.;|
| Local antibiotics<br> | Other: No intervention<br>* No intervention<br>* Other names: Since our study was observational after the beginning of treatment with or without antibiotics no intervention was influenced by the study.;|
| No antibiotics<br> | Other: No intervention<br>* No intervention<br>* Other names: Since our study was observational after the beginning of treatment with or without antibiotics no intervention was influenced by the study.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

Study Overview
=================
Brief Summary
-----------------
The use of MDS to access the presence of melanoma in the skin.

Detailed Description
-----------------
A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to provide a score that correlates with the probability for the presence of melanoma in the lesion.

Official Title
-----------------
Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)

Conditions
-----------------
Skin Lesion

Intervention / Treatment
-----------------
* Device: MDS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals with skin lesion with one or more of the ABCDE features and recommended for a skin biopsy. The lesion is accessible to the imaging device, with at least 1 cm of skin around the lesion that is accessible to the MDS. Male and female ≥ 21 years old. Subject is capable of giving written informed consent. Primary excision. Exclusion Criteria: The lesion is less than 1 cm from the eyes. The lesion is on the palms of hands or soles of the feet. Mucosal lesion. Pregnant females. Low study procedure compliance. Patients who are mentally or physically unable to comply with all aspects of the study. Undergoing chemotherapy. Minor or legally incompetent and not able to sign the consent form. Patient previously tested by MDS and was diagnosed with melanoma during the study. Sensitivity to fluorescein

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Suspicious skin lesions.<br>Patients with a suspicious skin lesion referred for a biopsy are tested using MDS | Device: MDS<br>* Patients with a suspicious lesion, referred for a biopsy is tested using MDS.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The MDS produces a score between 1 to 10. | The score is a composite of the images of the mole, plus demographic and clinical information. The score is ranked from 1 to 10, with 1 being the lowest risk for melanoma, and 10 being the highest risk. | 28 days |
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Official Title
-----------------
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: immunity therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.Diagnosed as advanced non-small cell lung cancer 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation Exclusion Criteria: The patient is diagnosed with small cell lung cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| KRAS mutation<br>patients carry with KRAS mutation | Drug: immunity therapy<br>* The patient receives immunotherapy<br>|
| ALK fusion<br>patients carry with ALK fusion | Drug: immunity therapy<br>* The patient receives immunotherapy<br>|
| ERBB2 mutation<br>patients carry with ERBB2 mutation | Drug: immunity therapy<br>* The patient receives immunotherapy<br>|
| MET skipping/amplication<br>patients carry with MET skipping/amplication | Drug: immunity therapy<br>* The patient receives immunotherapy<br>|
| RET fusion<br>patients carry with RET fusion | Drug: immunity therapy<br>* The patient receives immunotherapy<br>|
| BRAF mutation<br>patients carry with BRAF mutation | Drug: immunity therapy<br>* The patient receives immunotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first) | January 2021- January 2021 (1 year) |
Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study

Study Overview
=================
Brief Summary
-----------------
Previously the investigators have found that adolescent elite swimmers, who have been involved in competitive swimming for only a few years, have not developed respiratory symptoms, signs of airway inflammation or airway hyperresponsiveness exept for a slight increase in airway responsiveness to eucapnic voluntary hyperpnea. In the current study, the investigators will be doing a 3-year follow-up study on the swimmers studied previously.

Detailed Description
-----------------
Even though studies suggest that elite sport can cause AHR and airway inflammation, more studies are needed to elucidate how and when AHR and airway inflammation develop; and there is a lack of follow-up studies. The present study will give us a chance to do a follow-up study to register changes in AHR and airway inflammation in athletes without any significant airway changes at baseline.

Official Title
-----------------
Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 15-19 years Part of the Danish National Swimming Association's talent program for young swimmers at the baseline study Informed consent Exclusion Criteria: Upper respiratory tract infection in the previous 4 weeks (visits will be postponed)

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Swimmers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Airway responsiveness to eucapnic voluntary hyperpnea and methacholine |  | Three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Airway inflammation |  | Three years |
CMR Exercise Stress Testing in HFpEF

Study Overview
=================
Brief Summary
-----------------
Patients of the University Hospital Göttingen with echocardiographic signs for diastolic heart failure and indication for right heart catheterisation will undergo additional diagnostic testing with CMR including exercise stress for detailed evaluation of diastolic dysfunction and tissue characterisation correlating the results with well-established clinical standards.

Official Title
-----------------
Cardiovascular Magnetic Resonance Real-time Exercise Stress Testing in Heart Failure With Preserved Ejection Fraction

Conditions
-----------------
Diastolic Heart Failure

Intervention / Treatment
-----------------
* Diagnostic Test: stress CMR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients with dyspnoea under stress, echocardiographic criteria for diastolic dysfunction (E/E'>8) and clinical indication for right heart catheterisation Exclusion Criteria: arrhythmia (brady- or tachycardic) bronchial asthma (allergic) incompliant patient pacemaker, ICD, non MRI-capable devices inability to use the ergometer in the MRI haemodynamic relevant valvular heart disease pulmonary disease (vital capacity or forced expiratory flow <80% of healthy control) angina pectoris post cardiac infarction anaemia (Hb <12 g/dl) uncontrollable hypertension (>150 mmHg systolic or >100 mmHg diastolic) age <18 years pregnancy claustrophobia renal insufficiency allergic to gadolinium based contrast agents

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: echocardiographic increase in left atrial pressure<br> | Diagnostic Test: stress CMR<br>* additional stress CMR to the established clinical diagnostics<br>|
| Other: echocardiographic no increase in left atrial pressure<br> | Diagnostic Test: stress CMR<br>* additional stress CMR to the established clinical diagnostics<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular magnetic resonance imaging | ventricular and atrial volumes | approx. 1 years | 
| Cardiovascular magnetic resonance imaging | ventricular and atrial mechanics: strain | approx. 1 years | 
| Cardiovascular magnetic resonance imaging | quantification of extracellular volume (ECV)/interstitial fibrosis | approx. 1 years |
Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the incidence and characteristics of eyelid inflammatory disorders during general ophthalmological consultations and to demonstrate association between palpebral pathologies and ocular surface pathologies.

Conditions
-----------------
Palpebral Pathologies, Ocular Surface Disease, Meibomian Gland Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation Patients informed of the objectives of the survey and agreeing to participate. Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Outpatients attending general ophthalmologic consultation<br>Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation Patients informed of the objectives of the survey and agreeing to participate. Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of eyelid disorders in general ophthalmological practice | Systematic description of the eyelid, the ocular surface and the dermatological aspect of the face Occurrence of Meibomian Gland Dysfunction(MGD). | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between palpebral pathologies and ocular surface pathologies | To describe association between palpebral pathologies and ocular surface pathologies | Day 1 | 
| Impact of eyelid disorder on patient's daily life | Consequences on vision, on daily life activities/work, on leisure, on contact lens wearing, on emotions, on sleeping, | Day 1 | 
| Current recommended strategy to treat eyelids disorders | Description of recommended strategy | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MGD, ocular surface pathologies
The Organ Protection of Astragalus in Subjects With Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.

Official Title
-----------------
The Cardiac and Kidney Protection of Astragalus in Subjects With Metabolic Syndrome

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Drug: low dose Astragalus
* Drug: high dose astagalus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18 years or older, meet the diagnostic criteria of MS non-allergic with the astragalus agree to conduct clinical trials and those who signed the informed consent Exclusion Criteria: patients with resistant hypertension renal disease requiring dialysis heart failure NYHA ⅢorⅣ; complications of diabetes arteritis cancer thyroid disease unstable coronary heart disease peripheral vascular disease acute cerebral vascular disease11.pregnancy、 planned pregnancy patients with anti-oxidants acute infection other organic dysfunction, such as the liver, respiratory system, blood system, and other rheumatic diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: High-dose Astragalus group<br>treatment with 10 gram astragalus | Drug: high dose astagalus<br> <br> |
| Active Comparator: Low-dose Astragalus group<br>treatment with 5 gram astragalus | Drug: low dose Astragalus<br> <br> |
| No Intervention: MS control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| index of cardiac function | ues echocardiography to measure the cardiac function | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood pressure |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
5-10 gram astragalus per day